Evidence map›Paper›PMID 42645359›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Aemélia Nègre, Lorène Seguin, Arthur Géraud Cremieux, Frederic Viret, Agnès Tallet, Cornel Popovici, Anthony Gonçalves, Alexandre de Nonneville

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aemélia NègreDepartment of Medical Oncology, Institute Paoli Calmettes, 13009 Marseille, France.
Lorène SeguinDepartment of Medical Oncology, Institute Paoli Calmettes, 13009 Marseille, France.
Arthur Géraud CremieuxDepartment of Medical Oncology, Institute Paoli Calmettes, 13009 Marseille, France.
Frederic ViretDepartment of Medical Oncology, Institute Paoli Calmettes, 13009 Marseille, France.
Agnès TalletDepartment of Radiotherapy, Institute Paoli Calmettes, CRCM, 13009 Marseille, France.
Cornel PopoviciCancer Biology Department, Institute Paoli Calmettes, 13009 Marseille, France.ORCID 0000-0001-8226-3127
Anthony GonçalvesDepartment of Medical Oncology, Institute Paoli Calmettes, 13009 Marseille, France.ORCID 0000-0001-7570-7439
Alexandre de NonnevilleDepartment of Medical Oncology, Institute Paoli Calmettes, 13009 Marseille, France.ORCID 0000-0001-6710-8284

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases in hormone receptor-positive metastatic breast cancer remain incompletely characterized at the molecular level. We report isolated central nervous system progression in a 60-year-old woman with hormone receptor-positive breast cancer initially diagnosed at the age of 38 and metastatic recurrence diagnosed at the age of 55. After approximately five years of extracranial disease control with letrozole plus palbociclib, she developed multiple brain metastases, including a large cerebellar lesion requiring surgical resection. Molecular profiling of the resected lesion identified

Indexed as

Brain NeoplasmsBreast NeoplasmsCirculating Tumor DNAEstrogen Receptor alphaErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedCirculating Tumor DNAErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphabreast cancer brain metastasescase reportcirculating tumor DNACNS progressionESR1 mutation

Identifiers

PMID42645359
PMCPMC13510483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.